ARCA announced a program to evaluate AB201, a potent, selective inhibitor of TF, as a potential treatment for COVID-19 associated coagulopathy. Read more...
Apellis has initiated a study of APL-9, an investigational C3 inhibitor designed for acute interventions, in COVID-19 patients with respiratory failure including ARDS. Read more...
The FDA took a new step to support the agency’s evaluation of diagnostic tests for COVID-19, by providing a SARS-CoV-2 reference panel. Read more...